Paroxetine Tablet, Film Coated, Extended Release
Product Images NDC 69367-336

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Paroxetine (NDC 69367-336). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Westminster Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Paroxetine 01)

Chemical structure diagram of paroxetine hydrochloride, showing its molecular framework including a fluorophenyl group and a piperidine ring fused with additional functional groups.*

FDA Label Image

Figure 1 (Paroxetine 02)

A pharmacokinetic fold change chart showing the effects of various interacting drugs (Pimozide, Desipramine, Propranolol, Digoxin, Phenytoin) on Cmax and AUC of Paroxetine extended-release tablets. The chart displays fold change values with 90% confidence intervals on a logarithmic scale representing change relative to reference.*

FDA Label Image

Figure 2 (Paroxetine 03)

A chart showing fold change and 90% confidence intervals of Cmax and AUC pharmacokinetic parameters for Paroxetine when taken with various interacting drugs: Cimetidine 300 mg three times daily, Phenobarbital 100 mg once daily, Phenytoin 300 mg once daily, Digoxin 0.25 mg once daily, and Diazepam 5 mg three times daily. The x-axis represents change relative to reference ranging from 0 to 2.*

FDA Label Image

Figure 3 (Paroxetine 04)

A chart depicting pharmacokinetic fold changes with 90% confidence intervals for Paroxetine in various populations, including mild, moderate, and severe renal impairment, hepatic impairment, elderly patients at different doses, and males. The x-axis shows fold change relative to reference on a logarithmic scale from 0.5 to 50, and markers indicate Cmax, Cmin, and AUC values.*

FDA Label Image

Principal Display Panel (12.5 mg Tablet Bottle Label)

Label for Paroxetine Extended-Release Tablets, USP 12.5 mg, film-coated extended-release oral tablets. The package contains 30 tablets. It is labeled for prescription use only and manufactured by Visum Pharmaceutical Co., distributed by Westminster Pharmaceuticals, LLC. The label includes storage instructions and safety warnings for pharmacists.*

FDA Label Image

Principal Display Panel (25 mg Tablet Bottle Label)

Label for Paroxetine Extended-Release Tablets, USP 25 mg by Westminster Pharmaceuticals, LLC. The film-coated extended-release oral tablets come in a 30-count package. The label includes storage instructions, prescribing guidance, manufacturer and distributor details, and a barcode.*

FDA Label Image

Principal Display Panel (37.5 mg Tablet Bottle Label)

Label for Paroxetine Extended-Release Tablets, USP 37.5 mg by Westminster Pharmaceuticals. The oral film-coated extended-release tablets are supplied in a container of 30 tablets. The label includes storage instructions, manufacturer and distributor details, and a barcode.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.